Ravi Kant
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ravi Kant has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Amteshwar Singh Jaggi
Department of Pharmaceutical Sciences and Drug Research, Punjabi University, Patiala, India
1 shared publication - Andreas Muschaweckh
Institute for Experimental Neuroimmunology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany
1 shared publication - Anjana Bali
Laboratory of Neuroendocrinology, Department of Pharmacology, Central University of Punjab, Ghudda, Bathinda, India
1 shared publication - Christian Peter
Institute for Experimental Neuroimmunology, Technical University of Munich School of Medicine, Munich, Germany 1
1 shared publication - Christopher Sie
Institute for Experimental Neuroimmunology, Technical University of Munich School of Medicine and Health , 81675 Munich
1 shared publication - Gildas Lepennetier
Institute for Evolution and Biodiversity, University of Münster, 48149, Germany
1 shared publication
Latest Publications
- Open Access
- 12 July 2022
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 219 (8)
IL-24 intrinsically regulates Th17 cell pathogenicity in mice
In certain instances, Th17 responses are associated with severe immunopathology. T cell–intrinsic mechanisms that restrict pathogenic effector functions have been described for type 1 and 2 responses but are less well studied for Th17 cells. Here, we report a cell-intrinsic feedback mechanism that controls the pathogenicity of Th17 cells. Th17 cells produce IL-24, which prompts them to secrete IL-10. The IL-10–inducing function of IL-24 is independent of the cell surface receptor of IL-24 on Th17 cells. Rather, IL-24 is recruited to the inner mitochondrial membrane, where it interacts with the NADH dehydrogenase (ubiquinone) 1 α subcomplex subunit 13 (also known as Grim19), a constituent of complex I of the respiratory chain. Together, Grim19 and IL-24 promote the accumulation of STAT3 in the mitochondrial compartment. We propose that IL-24–guided mitochondrial STAT3 constitutes a rheostat to blunt extensive STAT3 deflections in the nucleus, which might then contribute to a robust IL-10 response in Th17 cells and a restriction of immunopathology in experimental autoimmune encephalomyelitis.
- 12 July 2022
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 219 (8)
Open AccessIL-24 intrinsically regulates Th17 cell pathogenicity in mice
In certain instances, Th17 responses are associated with severe immunopathology. T cell–intrinsic mechanisms that restrict pathogenic effector functions have been described for type 1 and 2 responses but are less well studied for Th17 cells. Here, we report a cell-intrinsic feedback mechanism that controls the pathogenicity of Th17 cells. Th17 cells produce IL-24, which prompts them to secrete IL-10. The IL-10–inducing function of IL-24 is independent of the cell surface receptor of IL-24 on Th17 cells. Rather, IL-24 is recruited to the inner mitochondrial membrane, where it interacts with the NADH dehydrogenase (ubiquinone) 1 α subcomplex subunit 13 (also known as Grim19), a constituent of complex I of the respiratory chain. Together, Grim19 and IL-24 promote the accumulation of STAT3 in the mitochondrial compartment. We propose that IL-24–guided mitochondrial STAT3 constitutes a rheostat to blunt extensive STAT3 deflections in the nucleus, which might then contribute to a robust IL-10 response in Th17 cells and a restriction of immunopathology in experimental autoimmune encephalomyelitis.
- Open Access
- 1 January 2013
- Published by The Korean Physiological Society and The Korean Society of Pharmacology in The Korean Journal of Physiology & Pharmacology
- Vol. 17 (2) , 111-120
Prolyl 4 Hydroxylase: A Critical Target in the Pathophysiology of Diseases
Kant R, et al. Korean J Physiol Pharmacol. 2013 Apr;17(2):111-120. http://dx.doi.org/10.4196/kjpp.2013.17.2.111
- 1 January 2013
- Published by The Korean Physiological Society and The Korean Society of Pharmacology in The Korean Journal of Physiology & Pharmacology
- Vol. 17 (2) , 111-120
Open AccessProlyl 4 Hydroxylase: A Critical Target in the Pathophysiology of Diseases
Kant R, et al. Korean J Physiol Pharmacol. 2013 Apr;17(2):111-120. http://dx.doi.org/10.4196/kjpp.2013.17.2.111